Navigation Links
Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
Date:3/20/2013

MAPLE GROVE, Minn., March 20, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., (Upsher-Smith) today announced the presentation of data supporting favorable tolerability and a predictable, consistent pharmacokinetic (PK) profile of USL255 at high doses following single-dose administration to healthy subjects.  USL255, an investigational once-daily, extended-release (ER) topiramate formulation is in development for the management of epilepsy in adults.  This data was presented at the 65th Annual American Academy of Neurology (AAN) Meeting in San Diego, CA (http://www.aan.com), March 16-23, 2013.

"Epilepsy drug therapy often must be carefully titrated in order to optimize benefit while minimizing adverse effects," said James Cloyd , PharmD, Professor and Lawrence C. Weaver Endowed Chair-Orphan Drug Development, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota.  "The introduction of extended-release formulations for a number of antiepileptic drugs offers the potential for management of seizures by decreasing the number of doses patients take on a daily basis and reducing the risk of adverse effects related to peak drug concentrations."

"At Upsher-Smith, we are committed to researching new treatment options for people living with challenging central nervous system conditions like epilepsy," added William Pullman, MB BS, BMedSc, PhD, FRACP, Chief Scientific Officer, Upsher-Smith.  "The data presented at AAN from the development program for USL255 adds to the existing body of evidence supporting the further development of USL255 for the once-daily management of epilepsy."

The abstract of the poster presentation can be found online at http://www.aan.com:

  • Single, High Doses of USL255, an Extended-Release Topiramate Formulation, are Well Tolerated and Demonstrate a Dose-Proportional Pharmacokinetic Profile in Healthy Subjects 
    P04.212. Session P04:  Epilepsy:  Antiepileptic Medications:  Special Populations and Pharmacokinetics

USL255 (Extended-Release Topiramate) Data

The objective of the single-dose, Phase I study was to determine the maximum tolerated dose (MTD), safety/tolerability, and pharmacokinetics (PK) of ascending doses of USL255 in healthy volunteers.  The study planned for sixty subjects to be randomized (4:1) to USL255 (600, 800, 1000, 1200, 1400 or 1600 mg) versus placebo.  PK samples were drawn, and tolerability and vital signs assessed, out to 14 days post-dose.  Escalation to the next dose level was done only after USL255 demonstrated suitable tolerability four days post-dose, assessed by a priori tolerability criteria.  Dose proportionality and linearity of topiramate exposure was determined using statistical models.  The study results showed single-ascending doses of USL255 were generally well tolerated from 600 – 1200 mg, with 1200 mg established as the MTD.  AUC and Cmax were dose proportional and linear over the entire 600 – 1400 mg dose range.

USL255 is an investigational treatment being developed for the management of epilepsy in adults and is also the subject of a global Phase III clinical trial (PREVAIL).  Information about the trial can be found at http://www.clinicaltrials.gov (NCT01142193).

Upsher-Smith's Epilepsy Pipeline

Upsher-Smith's clinical development pipeline includes three investigational drugs that are being studied for the management of epilepsy.  USL255 is an investigational once-daily, extended-release topiramate for the management of epilepsy.  The pipeline also includes USL261, an investigational intranasal midazolam for the rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity, often called seizure clusters, which is the subject of an ongoing international Phase III clinical trial (ARTEMIS1) with an open-label safety extension study.  In addition, USL260 (tonabersat), is in early clinical development as a potential first-in-class neuronal gap junction modulator.  

About Epilepsy

Epilepsy is a medical condition that causes seizures affecting a variety of cognitive and physical functions.  More than two million people in the U.S. are estimated to be affected by epilepsy with about 200,000 new cases of epilepsy diagnosed each year.For many people with epilepsy, medication will prevent seizures if taken regularly, but some people continue to have seizures.1  As many as two out of three patients treated for epilepsy have seizures that are refractory to therapy.2    

About Upsher-Smith

Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded, branded-generic and generic pharmaceuticals.  Upsher-Smith has a particular focus on providing therapies to assist people suffering from central nervous system diseases (including epilepsy, Parkinson's disease and Alzheimer's disease) and also markets products relating to cardiology, dermatology, and women's health.  For more information, visit www.upsher-smith.com.

1.

Epilepsy Foundation. Available at: http://www.epilepsyfoundation.org/.  Accessed on March 7, 2013.

2.

Epilepsy.com.  Available at http://professionals.epilepsy.com/secondary/Refractory_Seizures.html.   


Accessed on March 5, 2013.

107740.01 


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
2. Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation
3. Upsher-Smith Is Honored with Prestigious Industry Award for Excellence and Innovation
4. Upsher-Smith Teams Up With Epilepsy Foundation of Minnesota for 2012 Stroll for Epilepsy
5. Tina Fehr, Senior Product Manager For AmLactin, Upsher-Smith Laboratories Named PM360 Trailblazer Winner For Womens Health Brand Manager
6. Doug Zitnak of Upsher-Smith Laboratories Named Small Brand Manufacturer Representative of the Year By Cardinal Health
7. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
8. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
9. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
10. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
11. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)...  Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully ... tests and pathology services, announced today the acceptance of ... United States and Canadian Academy of ... San Antonio, Texas . ... the Company,s extensive experience in molecular thyroid testing, including ...
(Date:2/27/2017)... CAESAREA , Israel and TAMPA, Fla. ... Heart Ltd., an emerging medical device company focused ... undergoing cardiac procedures, applauds the members of the ... past week for their acknowledgement of the need ... (TAVR) surgery. "The statements shared by ...
(Date:2/27/2017)... Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... development company focused on tissue protection, repair and ... GtreeBNT Co., Ltd., received a positive response from ... trial design for RGN-137 to treat epidermolysis bullosa ... that incorporates Thymosin beta 4 ("Tß4") as the ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... ... The threat of nuclear warfare has long plagued this world. In July ... testing of nuclear weapons. Years later, when her co-workers began dying, Dot started searching ... Testing,” Clayton exposes the critical decisions made by agencies involved in the nuclear testing ...
(Date:2/27/2017)... , ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. ... has disclosed that despite scientific studies, the Center for Disease Control ( CDC ) ... disease . Kenneth B. Liegner, M.D. has compiled into a single volume a ...
(Date:2/27/2017)... ... 2017 , ... New Jersey ranks among the top five states in the ... need for advanced services is growing. , Project WE vs C is a ... with their non-profit partners in their fight against cancer and in support of their ...
(Date:2/26/2017)... York, New York (PRWEB) , ... February 26, ... ... luxury baby products for wholesale distribution in North America, today announced it would ... online sites. The company, which prides itself on crafting quality and unique baby ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide exposure is linked ... LRRK2 mutation, according to a study released today at the 1st Pan American ... link between pesticides and incidence of sporadic PD through occupational exposure. This latest ...
Breaking Medicine News(10 mins):